Consortium raises €21m for AgomAb

V-Bio Ventures closed its Fund 1 ARKIV on €76m in 2016. Advent France Biotechnology held a first close for its Advent France Biotechnology Seed-Fund I on €64.75m in 2017.

Following the transaction, John Haurum has been appointed as chair of the company's board of directors. A representative from each investor in the round has also joined the board.

Company
AgomAb is a biotherapeutics company that develops agonistic antibodies for the regeneration of damaged tissues. Founded in 2017, the company has produced a comprehensive pre-clinical package illustrating a range of applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases. The company is based in Ghent.

People
V-Bio Ventures - Katja Rosenkranz (partner).
Advent France Biotechnology - Matthieu Coutet (managing partner).
Boehringer Ingelheim Venture Fund - Ilka Wicke (director, investment manager).
Omnes - Claire Poulard (associate).
Pontifax  - Ohad Hammer (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Benelux
• Healthcare
• Venture
• Omnes Capital
• Belgium
• healthcare